Navigation Links
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Date:5/14/2013

lds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor being developed in advanced breast and lung cancer. Randomized, placebo-controlled phase 2 studies with entinostat have demonstrated promising results in combination with aromatase inhibitors in breast cancer (ENCORE 301) and with the EGFR-TKI erlotinib (ENCORE 401) in non-small cell lung cancer providing the basis for moving entinostat into pivotal, phase 3 testing across a platform of solid tumor indications. NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement. The company is supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. Formed in 2005, Syndax's intellectual property is based on work from scientific founder Ronald Evans , Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. For more information please visit www.syndax.com.

Contacts:
Peter Ordentlich
Syndax Pharmaceuticals, Inc.
pordentlich@syndax.com  
T: (781) 419-1412


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
(Date:7/31/2015)... N.J. and SAN DIEGO ... that its parent company Eisai Co., Ltd. (Headquarters: ... Naito , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Dr. Helen Torley , "NASDAQ: HALO") have signed ... (brand name: Halaven ® , "eribulin") in combination with ...
(Date:7/31/2015)... 31, 2015  Xencor, Inc. (NASDAQ: XNCR ), ... the treatment of autoimmune diseases, asthma and allergic diseases, ... S. Hata to its board of directors. ... corporate development is a tremendous asset to our board," ... executive officer of Xencor. "Xencor faces a range of ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
... 28, 2011  CIVCO Medical Solutions is introducing RAD-GUIDE, ... at RSNA 2011. RAD-GUIDE allows physicians a method ... visualizing and adjusting planned punctures prior to needle ... to translating our expertise in ultrasound needle guidance ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2CIVCO Enters CT Needle Guidance Market with RAD-GUIDE™ Launch 2
(Date:7/30/2015)... ... July 31, 2015 , ... ... By 50% or More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. ... 15 year veteran of helping drug, biologic and device firms reduce manufacturing errors ...
(Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a ... app invention that can help people during emergencies. , "The worldwide mobile health ... Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile health ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
(Date:7/30/2015)... ... , ... In an effort to provide the twenty four hour continuous care ... his practice. , The decision will also allow him to spend more time in ... his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2
... Doctors use diagnostic sonography or ultrasound to visualise organs ... researcher Koos Huijssen has developed a computer model that ... ultrasound instruments. The computer model is capable of processing ... both a PC and a parallel supercomputer. Erasmus University ...
... American Society of,Hematology (ASH), the world,s largest professional ... its Executive Committee, the,governing body of the organization. ... 2009., J. Evan Sadler, MD, PhD, will ... successive terms as president-elect and president. Charles,Abrams, MD, ...
... Nov. 4 Election Day statement by,SEIU President Andy ... Tacoma, Washington, who lost,her home and all her savings ... -- will vote today., "Samara Knight -- a ... can,t afford her mortgage payments and the,medication her son ...
... HOLLYWOOD, Calif., Nov. 4 IPC The,Hospitalist Company, Inc. ... practice company, announced today that Adam D. Singer,Chief Executive ... scheduled to present on Wednesday, November 12, 2008 at ... AZ., Event: 2008 Annual Credit Suisse ...
... Allied Minds funds research to reduce,wrinkles by developing ... a seed investment firm specializing in early stage ... Berkeley National,Laboratory through creation of start-up company, ProGDerm, ... Mina Bissell will develop a,technology based on modulation ...
... Will Sell Programming Kit and Software ,Separately From its Hearing Aids ... ... November 4, 2008 -- America Hears, Inc. , the leading ... improved version of its hearing-aid programming software, Virtual Office, and announced ...
Cached Medicine News:Health News:New Leadership Elected to the American Society of Hematology 2Health News:Today We Must Be the Change We Need 2Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference 2Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 3
... and soft tissue reconstructions, and in ... is sometimes necessary to encourage host ... minimizing tissue attachment along another surface.,GORE ... ePTFE sheet material that offers a ...
... Repair CompanySM is pleased to announce the ... Bard Composix E/X mesh.,When Bard Composix mesh ... first ventral hernia repair prosthesis that combined ... and ePTFE, in one product. Bard Composix ...
... 1958, Bard mesh has become the standard ... Bard mesh was used by Dr. Irving ... hernia repair many years ago. Lichtenstein describes ... substance for permanent reinforcement of hernia repair. ...
... mesh is a three-dimensional, anatomically formed prosthesis ... Bard 3DMax mesh has been designed based ... the inguinal canal. The result is a ... Bard 3DMax product is constructed of Bard ...
Medicine Products: